More randomised controlled studies in speech and language therapy by Carding PN & Hillman R
success stories have been documented: in many north›
ern European countries an aggressive “search and
destroy” policy combined with prudent use of antibiot›
ics has resulted in clinical environments that are essen›
tially free of MRSA.
In the Netherlands, for instance, the annual
number of MRSA strains submitted for epidemiologi›
cal typing to the National Institute for Public Health
and the Environment has risen from less than 200 in
the early nineties to about 500 to date.7 The number of
index patients has also increased, but less steeply. How›
ever, the overall percentage of MRSA among clinical S
aureus isolates is still well below 1%, and no additional
resistance features, such as reduced susceptibility to
glycopeptides, have emerged. Infections with resistant
strains are commoner in patients without a recent his›
tory of foreign travelling, which suggests that local
MRSA strains, mostly of known epidemic types, are
encountered more frequently. The situation in relation
to MRSA in nursing homes and hospitals is still under
control, however. It is clear from the Dutch experience
that MRSA elimination should combine both infection
control and policies to control the use of antibiotics.
It is unclear what the future will bring: countries
bordering nations reporting successful anti›MRSA
policies are faced with increasing incidences of MRSA,
which in turn increase the pressure on the countries
with limited MRSA endemicity. In addition, MRSA
used to be primarily a problem of nosocomial spread,
but recent reports indicate significantly rising numbers
of MRSA in populations outside hospital.8 Thus it
seems that MRSA is here to stay and that modulation
of antibiotic policies alone will not ultimately be
sufficient to eliminate MRSA from clinical settings.
We therefore need to find alternative strategies for
eliminating MRSA carriage. Von Eiff et al have recently
shown that S aureus cells can be killed in vitro by the
shock waves that are used for extracorporeal
lithothripsy.9 Whether this approach will turn out to be
helpful in eradicating this sophisticated bacterial
pathogen is doubtful, however. Osmolyte stimulation
of innate antimicrobial defence systems might be a
more promising approach,10 but bacteriophage
therapy11 or bacterial interference strategies, which
could lead to elimination of the “weakest” strains,
should also be explored further (J Nouwen et al,
unpublished).4
In the meantime, however, there are useful actions
that clinicians can take. Strict hand hygiene policies
may already be achieving some success in the battle
against nosocomial transmission of MRSA.12 Further›
more, Von Eiff et al have recently shown that most
infections caused by staphylococci can be traced back
to prior nasal carriage by certain patients,13 which
suggests that elimination of nasal carriage still is a use›
ful intervention.
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More randomised controlled studies in speech and
language therapy
Complex behavioural interventions can be evaluated
Randomised controlled trials remain the mostwidely accepted way of evaluating newtreatments. Clinical services such as speech
and language therapy, however, have been particularly
reluctant to produce randomised controlled trials as
evidence of efficacy of treatment.1 2 An evidence base is
emerging for the efficacy of a number of speech and
language therapy interventions, especially in dyspha›
sia, stammering, laryngectomy, and dysphonia.3 Most
interventions, however, have been evaluated by uncon›
trolled before and after comparisons. One of the first
randomised controlled trials in speech and language
therapy to evaluate voice therapy in dysphonia appears
in this issue.4 This trial shows that it is possible to
design and carry out randomised controlled trials to
examine complex behavioural interventions.
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Randomised controlled studies are difficult to
apply in some areas5; the limitations of such trials in
general medicine, surgery, and behavioural therapies
are well documented.2 6 7 Researchers in speech and
language therapy have been reluctant to use ran›
domised controlled designs because of the complexity
and individuality of human communication behaviour,
the consequent difficulties in standardising the content
and delivery of specific intervention programmes, and
the problem of measuring outcomes of a multifaceted
phenomenon. The methods of randomised controlled
trials are not appropriate in many areas of current
clinical research—for example, exploratory research
into factors related to health that influence speech and
language behaviour.8 Also, it may not be possible for
studies of behavioural treatments to meet all the crite›
ria typically used to define the control group in a ran›
domised study or to use blind or placebo treatment.
Study of the individual, psychosocial, and cultural
components of a speech or language disorder requires
good qualitative research to establish promising inter›
ventions.
Despite these difficulties, important randomised
controlled trials in speech and language therapy have
been done in recent years.1 In the trial described in this
issue the application of a randomised controlled
design was successful because the authors were able to
evaluate interventions with well defined treatment
objectives.4 The authors wisely confined the study to a
number of well established techniques in voice therapy
but did not restrict the treatment variable to an unreal›
istic degree. Voice therapy for dysphonia consists of a
series of techniques that aim to correct maladaptive
and inappropriate vocal behaviours.8 9 The selection
and emphasis of particular behavioural techniques are
based on the specific nature of a person’s observed
vocal pathophysiology and the contributing psycho›
logical, occupational, and social influences.10 These
individual treatment programmes constitute a com›
plex intervention and therefore require careful
handling in a randomised controlled trial.11
The evaluation of a complex intervention often
requires multidimensional assessment because of the
absence of a single standard outcome measure that can
encompass the complexity of the disorder. A package
of outcome measures to reflect the nature of voice dis›
orders was used in this trial. The human voice is a
complex phenomenon that involves anatomical struc›
tures, physiological mechanisms, acoustic output—the
voice we hear—and associated psychosocial factors that
are unique to each person. Hence a variety of
assessments is used to measure various aspects of voice
production before and after treatment. However,
regardless of the phenomenon being evaluated, it is
difficult to achieve statistically significant results across
a number of related measures, especially in studies with
small numbers of participants.12 Alternatively, a strong
correlation between different measures is convincing
evidence of change, even if some results in themselves
are not significant.13
Clinical trials of complex behavioural treatments
such as voice therapy are most meaningful when the
trials combine measures giving insights into the impact
of specific underlying structures or mechanisms
(impairment) with measures that reflect disability or
handicap. In the evaluation of most behavioural thera›
pies, assessment of disability (limitation of perform›
ance) and handicap (loss of social function) often prove
more valuable than assessment of impairment (an
abnormality in physical or mental functioning). Conse›
quently, reliable questionnaires on disability or
handicap in specific diseases have become valuable
outcome measures.14 This point is illustrated in the
study under discussion, where a measure of impair›
ment (a laryngoscopic judgment) was not sufficiently
refined or sensitive to reflect change in outcome.4
However, end points relating to disability and handicap
that were judged by the patients differed significantly
between the treatment groups.
The use of a randomised controlled design does
not prevent further qualitative analysis of “the active
ingredients” of the therapy.2 Careful documentation of
individual differences in a treatment programme is a
vital component of evidence based practice. Similarly,
tracking the factors that are suspected to contribute to
individual patients’ disorders (for example, vocal
demands or hydration levels) allows retrospective
analysis (correlation), so that more patient specific
schemes for predicting response to treatment can be
developed.
In studies of complex human behaviour it can be
difficult to represent accurately the nature of particular
treatment programmes and to determine a satisfactory
set of outcome measures. To be successful these studies
need a pragmatic approach whereby the effectiveness
rather than efficacy of the treatment is measured. To
produce high quality scientific results in this context is
acknowledged as being difficult.2 7 13 The benefits may,
however, be great, because only studies of effectiveness
can contribute to a meaningful evidence base and
bring about a change in clinical practice.7
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